An insider of BDX has filed a notice of proposed sale of 1,610 shares of common stock through Morgan Stanley Smith Barney LLC, with an aggregate market value of $333,946.20, to be sold on or about 01/15/2026 on the NYSE. The shares were acquired from the issuer via 1,010 performance stock units on 11/26/2025 and the cash exercise of 600 stock options on 01/15/2026. Shares outstanding are listed as 285,418,551. During the prior three months, a Rule 10b5-1 plan for Michael Garrison sold 629 common shares for gross proceeds of $123,302.87.
Becton, Dickinson and Company (BD) reports that its BD 401(k) Plan will experience a temporary blackout period for the BD Common Stock Fund in connection with a pending transaction with Waters Corporation. The blackout is being implemented so the Plan can add Waters Common Stock Fund interests to participant accounts. It will begin after the market closes on the closing date of the Waters transaction and is expected to end during the week following that closing date.
During the blackout, Plan participants will not be able to carry out transactions involving the BD Common Stock Fund, including exchanges into or out of the fund, loans or partial withdrawals from amounts invested in the fund, or final distributions if any portion of their accounts is invested in the fund. BD shareholders and other interested parties can obtain the actual beginning and ending dates of the blackout period and related information at no charge by contacting Fidelity at the phone number provided.
Becton Dickinson & Co. executive vice president and Chief ISC Officer David Shan reported a routine share withholding related to equity compensation. On 01/03/2026, 44 shares of Becton Dickinson common stock were withheld at a price of $0 to cover taxes due on the vesting of previously reported restricted stock unit awards. After this transaction, Shan beneficially owns 8,926 shares of common stock in direct ownership.
Becton, Dickinson and Company insider plans small stock sale under Rule 144. A person identified as Michael Feld has filed a notice to sell 74 shares of the company’s common stock through a broker on the NYSE, with an aggregate market value of approximately $14,512.88. The shares come from restricted stock units acquired on 08/20/2025.
The filing also lists prior sales over the past three months under a Rule 10b5-1 trading plan, including 75 shares sold on 12/01/2025 for gross proceeds of $14,502.00 and 57 shares sold on 10/27/2025 for gross proceeds of $10,602.57. The filer represents that they are not aware of any undisclosed material adverse information about the issuer’s current or future operations.
Becton Dickinson & Co. executive Michael Feld, who serves as EVP, CRO and President of Life Sciences, reported a small stock sale. On 12/26/2025, he sold 74 shares of Becton Dickinson common stock at a price of $196.08 per share. After this transaction, he beneficially owned 16,506 shares directly.
The filing notes that this transaction was carried out under a Rule 10b5-1 trading plan that Feld adopted on February 7, 2025. Such plans allow insiders to pre-arrange trades according to set instructions, helping separate their personal trading activity from the timing of any nonpublic information they may hold.
Becton, Dickinson and Company is asking shareholders to vote at its virtual 2026 annual meeting on four items: electing 13 directors, ratifying Ernst & Young as independent auditor, approving named executive officer pay on an advisory basis, and increasing the shares available under its 2004 equity-based compensation plan by 3,935,000 shares.
The materials highlight record fiscal 2025 revenue of $21.8 billion, GAAP EPS of $5.82 and record adjusted diluted EPS of $14.40, supported by margin expansion from its BD Excellence program. BD returned $2.2 billion to shareholders through buybacks and dividends and marked its 54th consecutive annual dividend increase.
BD also describes the planned Reverse Morris Trust transaction combining its Biosciences and Diagnostic Solutions businesses with Waters Corporation, which is expected to generate about $4 billion in cash for BD and give its shareholders roughly 39% ownership of the new life sciences company, alongside extensive detail on governance, sustainability goals and risk oversight.
Becton Dickinson & Co executive Michael David Garrison reported selling 629 shares of common stock at $196.03 per share on December 17, 2025. After this sale, he directly owns 13,105 shares.
Garrison serves as EVP & Pres Med.Essntl&BioPharm, and the sale was made under a Rule 10b5-1 plan he adopted on August 13, 2025.
A shareholder of BDX has filed a notice under Rule 144 to sell 629 shares of common stock through Morgan Stanley Smith Barney LLC on the NYSE, with an approximate sale date of 12/17/2025. The planned sale has an aggregate market value of $123,529.31, compared with 285,418,551 shares of the same class reported as outstanding.
The shares to be sold were acquired on 11/26/2025 as Restricted Stock Units from the issuer, in an amount of 629 units, with the same date listed as the date of payment and the nature of payment noted as "N/A." By signing the notice, the seller represents that they do not know of any material adverse information about the issuer’s current or prospective operations that has not been publicly disclosed.
Becton Dickinson & Co. reported the equity holdings of its interim CFO, Vitor Roque, as of 12/05/2025. He beneficially owns 4,477 shares of common stock, which includes shares held directly and restricted stock units granted under the company’s 2004 Employee and Director Equity-Based Compensation Plan.
Roque also holds multiple grants of stock appreciation rights covering various amounts of common stock, with grant dates from 11/26/2018 through 11/26/2025, exercise prices ranging from $222.60 to $251.06, and expiration dates between 11/26/2027 and 11/26/2034. These rights vest in four annual installments beginning one year from each grant date and are held directly. A power of attorney authorizing Donna Kalazdy to sign on Roque’s behalf is also referenced.